Actionable news
All posts from Actionable news
Actionable news in AMGN: Amgen Inc.,

​AcelRx ACRX Zalviso Phase 3 data due Tuesday; InVivo NVIV halts INSPIRE trial

Price and Volume Movers

AcelRx Pharmaceuticals, Inc. (Nasdaq: ACRX) announced that it will hold a conference call on Tuesday, August 1 at 8:30 am EST to discuss top-line results from its Phase 3 IAP312 trial of Zalviso for the treatment of moderate-to-severe acute pain. Shares closed up 7% to $3.90.

InVivo Therapeutics Holdings Corp. (NVIV) shares slid to close down 27% to $1.80. The company announced the temporary halt in its Inspire trial of its Neuro Spinal Scaffold implant due to the death of the most recent patient to enroll into the trial. While the third death in the trial has been deemed to be unrelated to the implant the company has decided to halt the trial until it determines whether or not a change in enrollment criteria is required. As a result of the temporary enrollment halt, the company anticipates completing enrollment 1H 2018 and submitting a Humanitarian Device Exemption (HDE) application 2H 2018.

Intercept Pharmaceuticals, Inc. (Nasdaq:ICPT) shares closed down 13% to $117.93. The company announced 2Q earnings together with data from its two Phase 3 trials of obeticholic acid (OCA) in patients with nonalcoholic steatohepatitis (NASH) with fibrosis or cirrhosis (CONTROL trial) and Primary Sclerosing Cholangitis (AESOP trial). The CONTROL trial met its primary endpoint. However, some concerns were raised from investors in respect to a patient death. As the company noted;

During the ongoing LTSE phase, there has been one patient death due to acute renal and liver failure. While Intercept determined it could not be ruled out that this was possibly related to treatment, the principal investigator and the...